NEW YORK (GenomeWeb News) – Exiqon said today that it has licensed microRNA analysis technology from Merck subsidiary Rosetta Inpharmatics.
The license covers real-time PCR technology used in quantitative miRNA analysis. The technology was developed for microRNA biomarker analysis at Merck.
Exiqon said it will use the technology in a product line for detecting miRNA that it plans to release later this year.
Financial terms of the agreement were not released.
“Being able to market quantitative real-time PCR products for miRNA analysis complements the current product offerings based on microarrays, in situ detection and knockdown products for miRNA research and expands Exiqon’s offerings for microRNA biomarker analysis,” said Exiqon CEO Lars Kongsbak.